A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
A phase 3 trial testing Ipatasertib, now recruiting.
Overview
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study is a phase 3 interventional study registered as NCT05862285, led by Hoffmann-La Roche, and recruiting when checked on 2026-09-11. Official title: An Open-Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Study. Planned enrolment is 100 participants (estimated). The study started in 2023-06-01 and primary completion is expected in 2033-03-01. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
Shares Roche / Genentech and the tag ctgov-ingest.
- TrialCevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Shares Roche / Genentech and the tag ctgov-ingest.
- TrialRO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
Shares Roche / Genentech and the tag ctgov-ingest.
- TreatmentEnglumafusp alfa
Shares Roche / Genentech and the tag ctgov-ingest.
- TreatmentADG126
Shares Roche / Genentech and the tag ctgov-ingest.
- TreatmentCevostamab
Shares Roche / Genentech and the tag ctgov-ingest.
- TreatmentRO7771950
Shares Roche / Genentech and the tag ctgov-ingest.
- TreatmentEmactuzumab
Shares Roche / Genentech and the tag ctgov-ingest.